Share on StockTwits

Zeltiq Aesthetics (NASDAQ:ZLTQ) announced its earnings results on Tuesday. The company reported $0.07 earnings per share for the quarter, beating the analysts’ consensus estimate of ($0.13) by $0.20, American Banking News reports. The company had revenue of $47.10 million for the quarter, compared to the consensus estimate of $34.93 million. Zeltiq Aesthetics’s revenue was up 79.1% compared to the same quarter last year.

Shares of Zeltiq Aesthetics (NASDAQ:ZLTQ) traded up 8.64% on Tuesday, hitting $16.59. The stock had a trading volume of 726,686 shares. Zeltiq Aesthetics has a 52 week low of $5.88 and a 52 week high of $24.79. The stock’s 50-day moving average is $15.67 and its 200-day moving average is $17.80. The company’s market cap is $620.5 million.

ZLTQ has been the subject of a number of recent research reports. Analysts at Cantor Fitzgerald reiterated a “positive” rating on shares of Zeltiq Aesthetics in a research note on Monday, May 5th. On a related note, analysts at JPMorgan Chase & Co. reiterated a “neutral” rating on shares of Zeltiq Aesthetics in a research note on Wednesday, April 30th. They now have a $20.00 price target on the stock. Finally, analysts at Canaccord Genuity cut their price target on shares of Zeltiq Aesthetics from $26.00 to $24.00 in a research note on Wednesday, April 30th. They now have a “buy” rating on the stock. Three investment analysts have rated the stock with a hold rating and five have given a buy rating to the company’s stock. Zeltiq Aesthetics has a consensus rating of “Buy” and a consensus target price of $23.40.

Zeltiq Aesthetics, Inc operates as a medical device development company. It engages in the design, development, and commercialization of non-invasive procedures for the reduction of unwanted fat tissue.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.